Floatz logo

Spartalizumab

Non-Functional Pancreatic Neuroendocrine Tumor

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Non-Functional Pancreatic Neuroendocrine Tumor cohort.

Asset / SponsorPhaseRating
Lanreotide
Ipsen
Phase 3BB
Ribociclib
M.D. Anderson Cancer Center
Phase 2B
Veliparib
Vanderbilt-Ingram Cancer Center
Phase 1CC
Capecitabine
Vanderbilt-Ingram Cancer Center
Phase 1CC
Cabozantinib
National Cancer Institute (NCI)
Phase 3NR

Same molecule, other indications

Spartalizumab is also rated in:

pancreatic adenocarcinomaActive
B
Indicative · Phase 3
57 / 100
View asset →
triple-negative breast carcinomaActive
CCC
Indicative · Phase 2
54 / 100
View asset →
melanomaActive
CCC
Indicative · Phase 3
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →